Results 261 to 270 of about 284,370 (314)

Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott, Eugene Moylan, Maree Colosimo, Giles Stratton, Thomas Chiu, Mahsa H. Kouhkamari, Maureen Hitschfeld, Jessica Michie, Richard De Boer   +8 more
wiley   +1 more source

Antibody-functionalized nanoporous silicon particles as a selective doxorubicin vehicle to improve toxicity against HER2+ breast cancer cells

Science and Engineering of Composite Materials
Camacho Alma Rosa Oaxaca, Rodríguez Sara Elisa Herrera, Mojica Óscar René Ochoa, Agarwal Vivechana, Pelayo Alexis Jazmín Preciado, Arízaga Gregorio Guadalupe Carbajal, Álvarez Ángel H., Carvajal Zaira Yunuen García, Velázquez Moisés Martínez, Gutiérrez Rodolfo Hernández   +9 more
doaj   +1 more source

MicroRNA-Gene Networks Distinguish Hormone Receptor Status in HER2-Low Breast Cancer: An Integrative Transcriptomic Analysis. [PDF]

Genes (Basel)
Carvalho E, Brandão A, Schmitt F, Vale N.   +3 more
europepmc   +1 more source

Characterization, immune cell phenotyping and differential gene expression analysis of brain metastases and primary breast cancer samples. [PDF]

Sci Rep
Gassner FJ, Rinnerthaler G, Castagnaviz V, Gonzalez-Martinez A, Parigger T, Drothler S, Greil R, Geisberger R, Kraus TFJ, Romagna A, Schwartz C, Ladisich B, Sotlar K, Hauser-Kronberger C, Alinger-Scharinger B, Steiner M, Zaborsky N, Gampenrieder SP.   +17 more
europepmc   +1 more source

Synergistic Inhibition of Angiogenesis and Tumor Progression by CD73 Inhibitor and Menstrual Blood Stem Cell-Derived Exosomes via miR-422a Upregulation in HER2-Positive Breast Cancer. [PDF]

Cancer Manag Res
Iravani NJ, Majidzadeh-A K, Arab S, Zarinfam S, Hasannejad F.   +4 more
europepmc   +1 more source

Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or <i>HER2</i>-mutant solid tumors. [PDF]

Future Oncol
Schram AM, Park JJ, Italiano A, Kitano S, Guo Y, Li J, Bedard PL, van Marcke C, Ko R, Lunger L, Klotz DM, Hussain J, Maier D, Erzen D, Planchard D, Prenen H, Clay TD, Park JO, Kim HD, Hernando-Calvo A, Maruki Y, Ponz-Sarvise M, Dumbrava E.   +22 more
europepmc   +1 more source